Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 453

1.

MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.

Alayed Y, D'Alimonte L, Helou J, Ravi A, Morton G, Chung HT, Haider M, McGuffin M, Zhang L, Loblaw A.

Radiother Oncol. 2019 Sep 26. pii: S0167-8140(19)33095-6. doi: 10.1016/j.radonc.2019.09.011. [Epub ahead of print]

PMID:
31564554
2.

Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.

Martell K, Mendez LC, Chung HT, Tseng CL, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Wronski M, Szumacher E, Ravi A, Loblaw A, Morton G.

Radiother Oncol. 2019 Sep 12. pii: S0167-8140(19)33063-4. doi: 10.1016/j.radonc.2019.08.017. [Epub ahead of print]

PMID:
31522882
3.

Feasibility of an MRI-only workflow for postimplant dosimetry of low-dose-rate prostate brachytherapy: Transition from phantoms to patients.

Nosrati R, Song WY, Wronski M, Pejović-Milić A, Morton G, Stanisz GJ.

Brachytherapy. 2019 Jul 20. pii: S1538-4721(19)30124-2. doi: 10.1016/j.brachy.2019.06.004. [Epub ahead of print]

PMID:
31337542
4.

Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?

Morton GC, Hoskin PJ.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1054-1056. doi: 10.1016/j.ijrobp.2019.04.036. No abstract available.

PMID:
31327413
5.

Potential applications of the quantitative susceptibility mapping (QSM) in MR-guided radiation therapy.

Nosrati R, Paudel M, Ravi A, Pejovic-Milic A, Morton G, Stanisz GJ.

Phys Med Biol. 2019 Jul 16;64(14):145013. doi: 10.1088/1361-6560/ab2623.

PMID:
31151120
6.

Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy.

Lee SL, Ravi A, Morton G, Loblaw A, Tseng CL, Haider M, Murgic J, Nicolae A, Semple M, Chung HT.

Brachytherapy. 2019 Sep - Oct;18(5):567-573. doi: 10.1016/j.brachy.2019.04.006. Epub 2019 May 22.

PMID:
31126856
7.

5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed.

Martell K, Cheung P, Morton G, Chung H, Deabreu A, Zhang L, Pang G, Alayed Y, Mamedov A, Gladwish A, Loblaw A.

Pract Radiat Oncol. 2019 Sep - Oct;9(5):354-361. doi: 10.1016/j.prro.2019.04.010. Epub 2019 May 16.

PMID:
31103715
8.

The role of vasodilator-stimulated phosphoprotein (VASP) in the control of hepatic gluconeogenic gene expression.

Tateya S, Rizzo-De Leon N, Cheng AM, Dick BP, Lee WJ, Kim ML, O'Brien K, Morton GJ, Schwartz MW, Kim F.

PLoS One. 2019 Apr 24;14(4):e0215601. doi: 10.1371/journal.pone.0215601. eCollection 2019.

9.

Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer.

Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G.

Radiother Oncol. 2019 Jun;135:170-177. doi: 10.1016/j.radonc.2019.03.007. Epub 2019 Mar 27.

PMID:
31015164
10.

Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.

Alayed Y, Loblaw A, Chu W, Al-Hanaqta M, Chiang A, Jain S, Chung H, Vesprini D, Morton G, Ravi A, Davidson M, Deabreu A, Mamedov A, Zhang L, Erler D, Cheung P.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1066-1073. doi: 10.1016/j.ijrobp.2019.04.006. Epub 2019 Apr 16.

PMID:
31002941
11.

The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform.

Hultman K, Scarlett JM, Baquero AF, Cornea A, Zhang Y, Salinas CBG, Brown J, Morton GJ, Whalen EJ, Grove KL, Koegler FH, Schwartz MW, Mercer AJ.

J Comp Neurol. 2019 Aug 15;527(12):2069-2085. doi: 10.1002/cne.24668. Epub 2019 Mar 9.

PMID:
30809795
12.

The Hypothalamic Arcuate Nucleus-Median Eminence Is a Target for Sustained Diabetes Remission Induced by Fibroblast Growth Factor 1.

Brown JM, Scarlett JM, Matsen ME, Nguyen HT, Secher AL, Jorgensen R, Morton GJ, Schwartz MW.

Diabetes. 2019 May;68(5):1054-1061. doi: 10.2337/db19-0025. Epub 2019 Feb 22.

PMID:
30796029
13.

Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience.

D'Alimonte L, Ravi A, Helou J, Morrison D, Mendez LC, Easton H, Morton G.

Brachytherapy. 2019 May - Jun;18(3):348-352. doi: 10.1016/j.brachy.2019.01.002. Epub 2019 Feb 2.

PMID:
30718175
14.

Glucoregulatory responses to hypothalamic preoptic area cooling.

Muta K, Matsen ME, Acharya NK, Stefanovski D, Bergman RN, Schwartz MW, Morton GJ.

Brain Res. 2019 May 1;1710:136-145. doi: 10.1016/j.brainres.2019.01.002. Epub 2019 Jan 2.

15.

Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain.

Scarlett JM, Muta K, Brown JM, Rojas JM, Matsen ME, Acharya NK, Secher A, Ingvorsen C, Jorgensen R, Høeg-Jensen T, Stefanovski D, Bergman RN, Piccinini F, Kaiyala KJ, Shiota M, Morton GJ, Schwartz MW.

Diabetes. 2019 Mar;68(3):654-664. doi: 10.2337/db18-0498. Epub 2018 Dec 6.

16.

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ.

Cell. 2018 Nov 15;175(5):1244-1258.e26. doi: 10.1016/j.cell.2018.09.051. Epub 2018 Oct 25.

PMID:
30454645
17.

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M 3rd, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343. doi: 10.1016/j.ijrobp.2018.09.039. Epub 2018 Oct 9.

PMID:
30312717
18.

Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy.

Shaaer A, Davidson M, Semple M, Nicolae A, Mendez LC, Chung H, Loblaw A, Tseng CL, Morton G, Ravi A.

Brachytherapy. 2019 Jan - Feb;18(1):95-102. doi: 10.1016/j.brachy.2018.08.006. Epub 2018 Oct 2. Review.

PMID:
30287271
19.

Distinct Neuronal Projections From the Hypothalamic Ventromedial Nucleus Mediate Glycemic and Behavioral Effects.

Faber CL, Matsen ME, Velasco KR, Damian V, Phan BA, Adam D, Therattil A, Schwartz MW, Morton GJ.

Diabetes. 2018 Dec;67(12):2518-2529. doi: 10.2337/db18-0380. Epub 2018 Sep 26.

20.

Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.

Murgic J, Morton G, Loblaw A, D'Alimonte L, Ravi A, Wronski M, Davidson M, Haider M, Commisso K, Zhang L, Chung HT.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):561-567. doi: 10.1016/j.ijrobp.2018.06.039. Epub 2018 Jul 2.

PMID:
30244878
21.

MRI-based automated detection of implanted low dose rate (LDR) brachytherapy seeds using quantitative susceptibility mapping (QSM) and unsupervised machine learning (ML).

Nosrati R, Soliman A, Safigholi H, Hashemi M, Wronski M, Morton G, Pejović-Milić A, Stanisz G, Song WY.

Radiother Oncol. 2018 Dec;129(3):540-547. doi: 10.1016/j.radonc.2018.09.003. Epub 2018 Sep 19.

PMID:
30243670
22.

The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines.

Chang AJ, McBride S, Keyes M, Chung HT, Davis BJ, Cox BW, Crook J, Demanes DJ, Hsu IC, Kamrava M, Krauss DJ, Morton G, Orio Iii PF, Roach Iii M, Venkat PS, Vigneault E, Zelefsky MJ.

J Clin Oncol. 2018 Sep 13:JCO1800626. doi: 10.1200/JCO.18.00626. [Epub ahead of print] No abstract available.

PMID:
30212298
23.

Does specialist review for patients with suspected heart failure predict better outcomes? An observational study on the utility of compliance with NICE guidelines.

Morton G, Philip L, Gilpin T, Chan PE, Guha K, Kalra PR.

BMJ Open. 2018 Aug 23;8(8):e021856. doi: 10.1136/bmjopen-2018-021856.

24.

High dose-rate brachytherapy in the treatment of prostate cancer.

Mendez LC, Morton GC.

Transl Androl Urol. 2018 Jun;7(3):357-370. doi: 10.21037/tau.2017.12.08. Review.

25.

Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure.

Morton G, Nasirova N, Sparks DW, Brodsky M, Sivakumaran S, Lambe EK, Turner EE.

J Neurosci. 2018 Aug 1;38(31):6900-6920. doi: 10.1523/JNEUROSCI.0023-18.2018. Epub 2018 Jun 28.

26.

Leptin regulation of core body temperature involves mechanisms independent of the thyroid axis.

Deem JD, Muta K, Ogimoto K, Nelson JT, Velasco KR, Kaiyala KJ, Morton GJ.

Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E552-E564. doi: 10.1152/ajpendo.00462.2017. Epub 2018 Jun 26.

27.

Randomised Phase II Feasibility Trial of Image-guided External Beam Radiotherapy With or Without High Dose Rate Brachytherapy Boost in Men with Intermediate-risk Prostate Cancer (CCTG PR15/ NCT01982786).

Vigneault E, Morton G, Parulekar WR, Niazi TM, Springer CW, Barkati M, Chung P, Koll W, Kamran A, Monreal M, Ding K, Loblaw A.

Clin Oncol (R Coll Radiol). 2018 Sep;30(9):527-533. doi: 10.1016/j.clon.2018.05.007. Epub 2018 Jun 11.

PMID:
29903505
28.

Design and synthesis of functionalized piperazin-1yl-(E)-stilbenes as inhibitors of 17α-hydroxylase-C17,20-lyase (Cyp17).

Blass BE, Iyer P, Abou-Gharbia M, Childers WE, Gordon JC, Ramanjulu M, Morton G, Arumugam P, Boruwa J, Ellingboe J, Mitra S, Reddy Nimmareddy R, Paliwal S, Rajasekhar J, Shivakumar S, Srivastava P, Tangirala RS, Venkataramanaiah K, Bobbala R, Yanamandra M, Krishnakanth Reddy L.

Bioorg Med Chem Lett. 2018 Jul 15;28(13):2270-2274. doi: 10.1016/j.bmcl.2018.05.040. Epub 2018 May 22.

PMID:
29803730
29.

Drug therapies in chronic heart failure: a focus on reduced ejection fraction.

Bolam H, Morton G, Kalra PR.

Clin Med (Lond). 2018 Mar;18(2):138-145. doi: 10.7861/clinmedicine.18-2-138. Review.

30.

The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation.

Wallis CJD, Morton G, Herschorn S, Kodama RT, Kulkarni GS, Appu S, Shayegan B, Buckley R, Grabowski A, Narod SA, Nam RK.

Br J Cancer. 2018 May;118(10):1399-1405. doi: 10.1038/s41416-018-0071-4. Epub 2018 Mar 29.

31.

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H.

JAMA Oncol. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039. Epub 2018 Jun 14.

32.

In Uncontrolled Diabetes, Hyperglucagonemia and Ketosis Result From Deficient Leptin Action in the Parabrachial Nucleus.

Meek TH, Matsen ME, Faber CL, Samstag CL, Damian V, Nguyen HT, Scarlett JM, Flak JN, Myers MG Jr, Morton GJ.

Endocrinology. 2018 Apr 1;159(4):1585-1594. doi: 10.1210/en.2017-03199.

33.

Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians.

Wallis C, Cheung D, Klotz L, Chalasani V, Leao R, Garisto J, Morton G, Nam R, Tannock I, Satkunasivam R.

Can Urol Assoc J. 2018 Feb;12(2):E59-E63. doi: 10.5489/cuaj.4736. Epub 2017 Dec 1.

34.

Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy.

Nicolae A, Murgic J, Kruljac I, Dubnitzky L, D'Alimonte L, Lu L, Cumal A, Law N, Morton G, Loblaw A, Chung HT, Ravi A.

Brachytherapy. 2018 Mar - Apr;17(2):306-312. doi: 10.1016/j.brachy.2017.10.015. Epub 2017 Nov 24.

PMID:
29239812
35.

Comparison of MOLLI, shMOLLLI, and SASHA in discrimination between health and disease and relationship with histologically derived collagen volume fraction.

Child N, Suna G, Dabir D, Yap ML, Rogers T, Kathirgamanathan M, Arroyo-Ucar E, Hinojar R, Mahmoud I, Young C, Wendler O, Mayr M, Sandhu B, Morton G, Muhly-Reinholz M, Dimmeler S, Nagel E, Puntmann VO.

Eur Heart J Cardiovasc Imaging. 2018 Jul 1;19(7):768-776. doi: 10.1093/ehjci/jex309.

PMID:
29237044
36.

Androgen receptor deficiency in monocytes/macrophages does not alter adiposity or glucose homeostasis in male mice.

Rubinow KB, Houston B, Wang S, Goodspeed L, Ogimoto K, Morton GJ, McCarty C, Braun RE, Page ST.

Asian J Androl. 2018 May-Jun;20(3):276-283. doi: 10.4103/aja.aja_54_17.

37.

Multidisciplinary team approach to heart failure management.

Morton G, Masters J, Cowburn PJ.

Heart. 2018 Aug;104(16):1376-1382. doi: 10.1136/heartjnl-2016-310598. Epub 2017 Nov 23. Review. No abstract available.

PMID:
29170356
38.

Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.

Mendez LC, Ravi A, Chung H, Tseng CL, Wronski M, Paudel M, McGuffin M, Cheung P, Loblaw A, Morton G.

Brachytherapy. 2018 Mar - Apr;17(2):291-297. doi: 10.1016/j.brachy.2017.10.001. Epub 2017 Nov 11.

PMID:
29137956
39.

Correlation of Fractional Flow Reserve With Ischemic Burden Measured by Cardiovascular Magnetic Resonance Perfusion Imaging.

Hussain ST, Paul M, Morton G, Schuster A, Chiribiri A, Perera D, Nagel E.

Am J Cardiol. 2017 Dec 1;120(11):1913-1919. doi: 10.1016/j.amjcard.2017.08.002. Epub 2017 Sep 4.

PMID:
29050683
40.

The Dorsal Medial Habenula Minimally Impacts Circadian Regulation of Locomotor Activity and Sleep.

Hsu YA, Gile JJ, Perez JG, Morton G, Ben-Hamo M, Turner EE, de la Iglesia HO.

J Biol Rhythms. 2017 Oct;32(5):444-455. doi: 10.1177/0748730417730169. Epub 2017 Sep 27.

41.

Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.

Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, Chung HT, D'Alimonte L, Krahn M, Morton G, Loblaw A.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):718-731. doi: 10.1016/j.clon.2017.08.002. Epub 2017 Sep 12.

PMID:
28916284
42.

Chronic hindbrain administration of oxytocin is sufficient to elicit weight loss in diet-induced obese rats.

Roberts ZS, Wolden-Hanson T, Matsen ME, Ryu V, Vaughan CH, Graham JL, Havel PJ, Chukri DW, Schwartz MW, Morton GJ, Blevins JE.

Am J Physiol Regul Integr Comp Physiol. 2017 Oct 1;313(4):R357-R371. doi: 10.1152/ajpregu.00169.2017. Epub 2017 Jul 26.

43.

The evolution of brachytherapy for prostate cancer.

Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, Morton GC, Horwitz EM.

Nat Rev Urol. 2017 Jun 30;14(7):415-439. doi: 10.1038/nrurol.2017.76. Review.

PMID:
28664931
44.

How Should We Think About the Role of the Brain in Glucose Homeostasis and Diabetes?

Deem JD, Muta K, Scarlett JM, Morton GJ, Schwartz MW.

Diabetes. 2017 Jul;66(7):1758-1765. doi: 10.2337/dbi16-0067. Epub 2017 Jun 11. No abstract available.

45.

Quantitative assessment of left ventricular mechanical dyssynchrony using cine cardiovascular magnetic resonance imaging: Inter-study reproducibility.

Kowallick JT, Morton G, Lamata P, Jogiya R, Kutty S, Hasenfuß G, Lotz J, Chiribiri A, Nagel E, Schuster A.

JRSM Cardiovasc Dis. 2017 May 15;6:2048004017710142. doi: 10.1177/2048004017710142. eCollection 2017 Jan-Dec.

46.

Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis.

Wallis CJD, Morton G, Jerath A, Satkunasviam R, Szumacher E, Herschorn S, Kodama RT, Kulkarni GS, Naimark D, Nam RK.

MDM Policy Pract. 2017 May 19;2(1):2381468317709476. doi: 10.1177/2381468317709476. eCollection 2017 Jan-Jun.

47.

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6.

PMID:
28433432
48.

Specialist intervention is associated with improved patient outcomes in patients with decompensated heart failure: evaluation of the impact of a multidisciplinary inpatient heart failure team.

Masters J, Morton G, Anton I, Szymanski J, Greenwood E, Grogono J, Flett AS, Cleland JG, Cowburn PJ.

Open Heart. 2017 Mar 8;4(1):e000547. doi: 10.1136/openhrt-2016-000547. eCollection 2017.

49.

Response to Leptin-deficient mice are not hypothermic, they are anapyrexic.

Kaiyala KJ, Ogimoto K, Nelson JT, Muta K, Morton GJ.

Mol Metab. 2017 Jan 26;6(4):313-314. doi: 10.1016/j.molmet.2017.01.008. eCollection 2017 Apr. No abstract available.

50.

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24.

PMID:
28262473

Supplemental Content

Loading ...
Support Center